The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-2410
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-11-07T06:01:53.356646Z
status: published
lens: g_space
sector: health
headline: Identification of plasma biomarkers for chronic kidney disease by integrating proteomics and machine learning
dek: Background Chronic kidney disease (CKD) is a major global health burden, and early identification of individuals at risk remains challenging. This study aimed to identify plasma proteomic biomarkers associated with incident CKD and develop a machine learning-based prediction model integrating proteomic and clinical data. Methods We conducted a prospective cohort study of 27,429 UK Biobank participants without baseline CKD after excluding those with estimated glomerular filtration rate Results A total of 205 prot…
gain_title: In a cohort study of 27,429 UK Biobank participants, adding four plasma proteins to a demographic model raised discrimination for incident chronic kidney disease to an AUC of 0.830, from 0.805 for demographics alone.
problem_title: (none)
trace_subject: (none)
gain_reading: In a cohort study of 27,429 UK Biobank participants, adding four plasma proteins to a demographic model raised discrimination for incident chronic kidney disease to an AUC of 0.830, from 0.805 for demographics alone.
gain_evidence: their combination improved discrimination (AUC, 0.830 [95% confidence interval, 0.806-0.855] | Integrating plasma proteomics with machine learning improves internal risk prediction for incident CKD
problem_reading: (none)
problem_evidence: (none)
quick_read: A prospective cohort study of 27,429 UK Biobank participants without chronic kidney disease at baseline used machine learning to find blood proteins that predict who develops the disease. Of 205 proteins significantly linked to incident CKD, the models narrowed the field to four: EDA2R, GDF15, HAVCR1 and SCARB2. Combined with demographic data, the panel reached an AUC of 0.830, up from 0.805 for the demographic model alone.

Early identification of people at risk of chronic kidney disease remains difficult, and the study describes the condition as a major global health burden. A compact four-protein panel could give clinicians complementary information for risk stratification. The authors say the result is an internal validation, so external validation is needed before any clinical use.
limitation: The improved prediction was assessed internally, and the authors say external validation is needed before the panel can be used clinically.
tag: Evidence-backed gain
key_points: The study followed 27,429 UK Biobank participants who did not have chronic kidney disease at baseline. | A total of 205 proteins were significantly associated with incident CKD. | LASSO selection identified 23 candidate proteins, and LightGBM narrowed these to four: EDA2R, GDF15, HAVCR1 and SCARB2. | The four-protein model alone performed comparably to the demographic model (AUC 0.796 vs 0.805; p = 0.14). | Combining the proteins with demographic data improved discrimination to an AUC of 0.830 (95% confidence interval 0.806-0.855). | SHAP and Kaplan-Meier analyses supported the predictive value of these proteins, and sensitivity analyses confirmed robustness.
rundown: Researchers used a prospective cohort design drawing on UK Biobank participants without baseline CKD. They tested which plasma proteins were associated with later kidney disease, finding 205 significant associations, then applied LASSO and LightGBM machine learning to select a smaller set.

The final four-protein panel (EDA2R, GDF15, HAVCR1 and SCARB2) matched a demographic model on its own, with AUCs of 0.796 and 0.805 (p = 0.14). Only the combination of proteins and demographic data improved discrimination, reaching 0.830, and it was assessed across prediction horizons up to 10 years.

SHAP and Kaplan-Meier analyses and sensitivity checks supported the findings. The authors conclude that the panel may add complementary information for risk stratification but that external validation is required before clinical application.
sources:
- peer_reviewed | Kidney Research and Clinical Practice | https://doi.org/10.23876/j.krcp.26.161 | 2026-11-02
prev: 0000000000000000000000000000000000000000000000000000000000000000

SHA-256 hash

1c871eb854a19ed7f3e71ae8a9fa5fef3f935b319ce9f4e945ca269fd5509801

Previous version’s hash

0000000000000000000000000000000000000000000000000000000000000000